SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?


To: Paul McWhinnie who wrote (62521)1/13/2000 5:46:00 PM
From: nolimitz  Respond to of 108040
 
More news on ISIP:

Thursday January 13, 4:28 pm Eastern Time
Isis and AstraZeneca Initiate Antisense Target Validation Program
CARLSBAD, Calif., Jan. 13 /PRNewswire./ -- Isis Pharmaceuticals (Nasdaq: ISIP - news) announced today that it has signed an antisense target validation agreement with AstraZeneca PLC to assess and prioritize genes identified within AstraZeneca's genomics programs. This program will use Isis' proprietary Antisense Target Validation technology to assist AstraZeneca in determining the function and therapeutic value of novel gene targets. Antisense technology provides an effective method of achieving specific inhibition of gene expression to validate potential drug targets or study gene function.

In the program, Isis will create antisense inhibitors to genes provided by AstraZeneca. Using the information gathered about the gene function, AstraZeneca will be able to better prioritize these candidates for pharmaceutical development. Financial details surrounding this research collaboration were not disclosed. This is Isis' third target validation collaboration.

``We are pleased that AstraZeneca is one of an expanding number of companies that recognize the value of antisense as a drug discovery tool,' said Stanley T. Crooke, Chairman and CEO Isis Pharmaceuticals, ``We anticipate that as pharmaceutical companies accumulate a growing number of gene targets from their work in genomics they will look to the efficiency and cost effectiveness of our antisense program to help alleviate this bottleneck in drug development.'

This press release contains forward-looking statements pertaining to the research collaboration between Isis and AstraZeneca PLC. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of drug discovery. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. These and other risks concerning corporate collaborations are described in additional detail in Isis' Annual Report on Form 10-K for the year ended December 31, 1998 which is on file with the U.S. Securities and Exchange Commission, copies of which are available from the company.

Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic drugs. The company's first product, Vitravene(TM) (fomivirsen), to treat CMV-induced retinitis in AIDS patients, is being sold in the United States, Europe, Brazil and Switzerland. In addition, Isis has four compounds in human clinical trials: a Phase II study of ISIS 2302 for the prevention of renal transplant rejection is near completion, Phase II studies of ISIS 2302 with an enema formulation for ulcerative colitis and a topical formulation for psoriasis, are just beginning and an aerosol administration of ISIS 2302 for asthma is being explored. In addition, Isis has three anticancer compounds: ISIS 3521, ISIS 5132 and ISIS 2503, in Phase II studies. The company also has several additional compounds in preclinical development. Isis' medicinal chemistry and biology research programs support efforts in both antisense and small molecule drug discovery.



To: Paul McWhinnie who wrote (62521)1/13/2000 5:48:00 PM
From: BarbaraT  Respond to of 108040
 
ASDS - here is an article written by Dan Dorfman that was out a few days back - thought I would share it with those that are long ASDS:


?Dan, congratulations on your wonderful stock pick last month. On your recommendation, I bought 1,200 shares of MarketCentral.net (MKTS) between 2 3/4 and 3 and I just sold out between 9 and 9 5/8. You probably guessed why I am writing you. Could you please recommend another stock, preferably one that involves the Internet and sells under $25? If we ever meet, by the way, the champagne is on me.?

Norman, thanks for the kind offer, but you should save the champagne for investment advisor Rick Eakle of Eakle Associates of Fair Haven, N.J., since he?s the one who picked the stock, not me.

He made that selection in my Dec. 6 report "Hot Hand, up 206% in 1999, Sees Big January Drop".

In that report, Eakle chose his five best stock ideas for the new year. So far, all five are up, with MarketCentral.net leading the way. The stock at the time of the report was 2 3/4, and Eakle projected a hefty rise to 25-30 over the next 12 months.

Whether it gets there or not is anybody?s guess, but the stock, since the report, has been a dazzler, more than tripling to 10 1/8.

It?s currently trading at 8 1/8, down 1 5/8.

Meanwhile, Eakle, who also manages a modest amount of private money (under $50 million), was 1999?s Superman, Batman and Lenox Lewis all wrapped up into one as he wound up the year, he tells me, with a 301% gain.

Getting back to Norman?s question, I asked Eakle if there was another Internet stock under 25 he liked, one that he felt could also generate a sharp rise over the ensuing 12 months.

His pick was ASD Systems (ASDS) 17 13/16, an Internet software and services company. In brief, it focuses on providing services to Internet retailers, such as billing, order processing, call center networks and e-commerce integration.

The company, incidentally, went public Nov. 11 at $8 a share. So it has already more than doubled its offering price.

Affiliates of Staubach Co., a firm headed by former Dallas Cowboys quarterback Roger Staubach, own 14% of the company?s stock.

Citing brisk customer need for the kind of software that ASD provides, Eakle sees strong growth ahead for the company, which had sales of $8 million over the past 12 months. Like many Internet companies, ASD is unprofitable, but Eakle expects it to break into the black in the next 12 to 18 months.

As for the stock, he sees it expanding to 30-35 over the next 12 months.

But given his negative view of the market for now, Eakle says he wouldn?t rush into buying the stock. He feels the 16-16 1/2 range is a good entry point.

A big plus for ASD, Eakle observes, is that it?s still an undiscovered, unexploited stock.

Though a bull on the 2000 market?he sees the Dow rising 25%-30% this year?Eakle is not enthusiastic about the near term.

A better-than-average market forecaster and once director of technical research at Morgan Stanley before it merged with Dean Witter, he feels excess speculation, coupled with mania-type buying, will lead to a 10%-15% selloff this month. And that selloff, he says, may well have kicked off yesterday.

* * *



To: Paul McWhinnie who wrote (62521)1/13/2000 5:52:00 PM
From: rdmsqito  Respond to of 108040
 
I'm seeing ASDS last trade 1k @ 15 3/4 with trades as high as 16 1/8. Can't find any news though?

nasdaq.com